Connect with us

Medicinal

New medical cannabis course to launch in January

Sativa Learning is launching is new medical cannabis course developed with The Medical Cannabis Clinicians Society.

Published

on

New medical cannabis course to launch in January

Sativa Learning is launching its new course on Monday, 10 January, 2021, which features expert-led content from pioneering cannabis clinicians in the UK.

The expert Sativa Learning course has been developed in conjunction with the UK’s Medical Cannabis Clinicians Society and is accredited by the Continuing Professional Development (CPD) Certification Service.

It aims to give participants a complete understanding of cannabis medicine, taking a deep dive into 10 conditions for which cannabis has been shown to be effective in treating.

New medical cannabis course to launch in January

Expert Dani Gordon educating on how to prescribe cannabis medicine for a range of women’s health conditions.

The course features expert-led educational content from nine doctors experienced in medical cannabis, personal accounts from nine medical cannabis patients, a mix of text and image-based learning as well as video content and references to more than 100 peer-reviewed medical cannabis papers.

Sativa Learning founder, Ryan McCreanor, commented: “We are delighted to launch our CPD Accredited Medical Cannabis Course in conjunction with the Medical Cannabis Clinicians Society. Doctors and patients have come together to develop the educational content which includes over two hours of video as well as text and image-based learning.”

Read more: Sativa Learning: on a mission to provide cannabis education

“The course has been specifically developed for medical students, doctors and healthcare professionals seeking a comprehensive understanding of cannabis as a medicine.

“We also take a deep dive into ten conditions for which cannabis is currently prescribed. Experienced clinicians discuss how they prescribe medical cannabis for each condition and patients comment on how a prescription has impacted their quality of life.

“We believe the medical cannabis industry should be patient-centric and we wanted to be sure their voices were heard.”

New medical cannabis course to launch in January

Behind the scenes of Marie Mills – fibromyalgia patient sharing her experience.

The course will consist of informal module quizzes and concludes with a final exam and students will earn a Medical Cannabis Course Certificate of Completion.

To find out more information or register for the course please visit www.sativalearning.com.

Medicinal

AMP exclusive enters cannabis extract distribution agreement in Germany

The three-year agreement will see AMP become the exclusive distribution partner for Australia-based Little Green Pharma. 

Published

on

AMP exclusive enters cannabis extract distribution agreement in Germany

AMP Alternative Medical Products  (AMP) and Little Green Pharma (LGP) have entered into the partnership for the distribution of full-plant cannabis extract oils in Germany.

The company, a wholly-owned subsidiary of Greenrise Global Brands, has been appointed as marketer and distributor of LGP medical cannabis extracts to pharmacies and clinics in Germany. 

This will include LGP’s 20:5 LGP Classic and 10:10 LGP Classic extract oils in 30 and 50 milliliter sizes.

The news follows AMP’s announcement earlier this week that the company entered into a marketing and distribution agreement for the sale of Dronabinol in pharmacies with Eurox Pharma in the country.

Managing director of Little Green Pharma, Fleta Solomon, commented: “We set the strategic objective to be one of the leading medical cannabis extract producers and distributors in Europe, which means being a leader in Germany, the largest medical cannabis market in the world. 

“Our partnership with Greenrise Global’s daughter company, AMP Alternative Medical Products GmbH, puts us on course to that path.”

Dr Stefan Feuerstein, president and director of Greenrise Global and managing director of AMP, commented: ”We are seeing the industry mature with the growth of pharmaceutical cannabis products over flowers and are excited about adding LGP medical cannabis extracts to our portfolio.”

LGP was among the first medical cannabis companies to produce and export medical cannabis oils to Germany.

The company is also the primary medical cannabis extract oil supplier in France’s two-year medical cannabis trials being conducted by the French National Agency for the Safety of Medicines and Health Products.

Continue Reading

Medicinal

AMP Alternative Medical Products begins Dronabinol sales in Germany

The company is a medical cannabis subsidiary of Greenrise Global Brands.

Published

on

AMP Alternative Medical Products begins Dronabinol sales in Germany
Home » News » Medicinal » New medical cannabis course to launch in January

AMP Alternative Medical Products (AMP) and Eurox Pharma have begun the sales of Dronabinol produced in Germany by Eurox.

Greenrise Global subsidiary, AMP and Eurox, a SEED Innovations Limited portfolio company and one of Europe’s leading medical cannabis companies, entered into a non-exclusive marketing and distribution agreement for Dronabinol for sale in pharmacies to begin in February 2022. 

In preparation for sales, AMP has trained its national sales team on the benefits of Dronabinol – a pure THC product primarily used in pain therapy – for patients to doctors and preparation methods for pharmacists.

Chairman of Eurox, Neil Smith, commented: “If you’re a believer in the ‘Made in Germany’, then that means Eurox. 

“AMP’s focus on serving German patients and its national sales coverage make them a perfect partner for us.”

Eurox was one of the first medical cannabis companies to produce Dronabinol made in Germany at one of Europe’s largest GMP facilities located in Hessen, Germany.

The company controls the entire supply chain from cultivation, production to distribution ensuring a stable and efficient supply to its customers.

AMP is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including medical cannabis brands from Aphria, Bedrocan, Little Green Pharma and AMP’s branded line of products.

Eurox began the white label sale of its dronabinol products to a number of select customers in November 2021. Eurox selected Materia Deutschland, a wholly-owned subsidiary of European medical cannabis and CBD wellness products Materia, as as a distribution partner for its medical cannabis extracts.

Continue Reading

Medicinal

Agreement aims to approve first cannabis vaporiser for European patients

A collaboration will see studies undertaken to prove the efficacy and safety of the device.

Published

on

Agreement aims to approve first cannabis vaporiser for European patients

German-based Eurox Group has entered into an exclusive agreement with the US multi-state Orchid Ventures.

Under the agreement, Eurox, PurTec and JWEI, the company’s original equipment manufacturer (OEM) supplier and partner, will submit one of PurTec’s premium disposable vaporiser devices to authorities in Germany for Medical Device Approval. 

The agreement is PurTec’s first European project.

Read more: Eurox begins sale of cannabis products in Germany

Founder, CEO and chairman of Orchid, Corey Mangold, commented: “After months of planning and strategising, we are pleased to announce our partnership with such an established group in Eurox.

“We’re thrilled to join forces with Eurox and to be submitting one of our most stringently tested vaping products for Medical Device Approval with German health authorities. 

“Once the product is accepted, this will be a huge step forward in our ability to deliver one of the first vaping products to patients and consumers in Germany along with several other European countries. 

“We are confident that with the combined experience and expertise of Eurox and JWEI, we will succeed in getting approval and be among one of the first vaporiser products in-market and available to consumers throughout the EU.”

Read more: Materia enters agreement with Eurox for cannabis extract distribution

The companies will be working on several requirements and safety studies to prove the efficacy and safety of the device, and have already begun securing various certifications to speed up the approval process. 

If and when approval is given for the device Eurox will have exclusivity regarding sales and distribution of the PurTec product in the European Union, United Kingdom and Brazil.

Co-CEO of Eurox, Dr Bernhard Babel, commented: “We are excited about this partnership. 

“We believe that PurTec and JEWI will be valuable, long-term partners that can help us expand access to relevant and exciting new products that will compliment our portfolio and advance our growth trajectory. 

“Our objective is to deliver with liquid vaping a controlled and consistent therapy form to patients with need for inhaling in Europe and beyond.”

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts